Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
์ข
๋ชฉ ์ฝ๋ SPRC
ํ์ฌ ์ด๋ฆScisparc Ltd
์์ฅ์ผDec 22, 2021
CEOWeiss (Amitay)
์ง์ ์2
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 22
์ฃผ์20 Raul Wallenberg Street, Tower A
๋์TEL AVIV-YAFO
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐIsrael
์ฐํธ ๋ฒํธ6971916
์ ํ97236103100
์น์ฌ์ดํธhttps://scisparc.com/
์ข
๋ชฉ ์ฝ๋ SPRC
์์ฅ์ผDec 22, 2021
CEOWeiss (Amitay)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์